Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 12, 2007, Pages 4351-4355

  Ambrose, Paul G ^a,b   Forrest, Alan ^a,b   Craig, William A ^c   Rubino, Chistopher M ^a,b   Bhavnani, Sujata M ^a,b   Drusano, George L ^a   Heine, Henry S ^d  

^a ORDWAY RESEARCH INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^d UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GATIFLOXACIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL INFECTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EXPOSURE; FEMALE; LETHAL DOSE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; MOUSE; NONHUMAN; POPULATION MODEL; PREDICTION; PRIORITY JOURNAL; PROBABILITY; SENSITIVITY ANALYSIS; SIMULATION; SURVIVAL;

AIR MICROBIOLOGY; ANIMALS; ANTHRAX; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; BACILLUS ANTHRACIS; DISEASE MODELS, ANIMAL; FEMALE; FLUOROQUINOLONES; HUMANS; MICE; MICE, INBRED BALB C; MONTE CARLO METHOD;

EID: 36749099392     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00251-07     Document Type: Article

References (25)

1. Akaike, H. 1974. A new look at the statistical model identification. IEEE Trans. Automatic Control 19:716-723.
2. Ambrose, P. G., D. M. Grasela, T. H. Grasela, P. Passarell, H. B. Mayer, and P. F. Pierce. 2001. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections Antimicrob. Agents Chemother. 45:2793-2797.
3. Amjbrose, P. G., S. M. Bhavnani, C. M. Rubino, A. Louie, T. Gumbo, A. Forrest, and G. L. Drusano. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 44:79-86.
4. Andes, D., M. L. van Ogtrop, J. Peng, and W. A. Craig. 2002. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob. Agents Chemother. 46:3484-3489.
5. Andes, R., and W. A. Craig. 2002. Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. Antimicrob. Agents Chemother. 46:1665-1670.
6. Bhavnani, S. M., J. P. Hammel, B. B. Cirincione, M. A. Wilder, and P. G. Ambrose. 2005. Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob. Agents Chemother. 49:3944-3947.
7. Centers for Disease Control and Prevention. 2001. Update: investigation of anthrax associated with intentional exposure and interim public health guidelines. Morb. Mortal. Wkly. Rep. 50:889-897.
8. Centers for Disease Control and Prevention. 2001. Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy. Morb. Mortal. Wkly. Rep. 50:909-919.
9. Clinical and Laboratory Standards Institute. 2006. Performance standards for antimicrobial susceptibility testing. Standard M100-S16. Clinical and Laboratory Standards Institute, Wayne, PA.
10. Craig, W. A. 2002. Pharmacodynamics of antimicrobials: general concepts and applications, p. 1-22. In C. H. Nightingale, T. Murakawa, and P. G. Ambrose (ed.), Antimicrobial pharmacodynamics in theory and clinical practice. Marcel Dekker, Inc., New York, NY.
11. 24/MIC for six fluoroquinolones against Streptococcus pneumoniae with survival and bactericidal activity in an animal model, abstr. 289. Abstr. 40th Intersci. Conf. Antimicrob. Chemother. American Society for Microbiology, Washington, DC.
12. D'Argenio, D. Z., and A. Schumitzky. 2003. ADAPT II user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles, CA.
13. Deziel, M. R., H. Heine, A. Louie, M. Kao, W. R. Byrne, J. Basset, L. Miller, K. Bush, M. Kelly, and G. L. Drusano. 2005. Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis. Antimicrob. Agents Chemother. 49: 5099-5106.
14. Drusano, G. L., K. H. P. Moore, J. P. Kleim, W. Prince, and A. Bye. 2002. Rational dose selection for a nonnucleoside reverse transcriptase inhibitor through use of population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob. Agents Chemother. 46:913-916.
15. Drusano, G. L., S. L. Preston, C. Hardalo, R. Hare, C. Banfield, D. Andes, O. Vesga, and W. A. Craig. 2001. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob. Agents Chemother. 45:13-22.
16. Fagle, H., R. Fleischman, and A. D. Musselman. 1950. The effective concentrations of penicillin in vitro and in vivo for streptococci, pneumococci, and Treponema pallidum. J. Bacteriol. 59:625-643.
17. Edberg, S. C. 1986. The measurement of antibiotics in human body fluids: techniques and significance, p. 382-399. In V. Lorian (ed.), Antibiotics in laboratory medicine, 2nd ed. Williams and Wilkins, Baltimore, MD.
18. Friedlander, A. M., S. L. Welkos, M. L. Pitt, J. W. Ezzell, P. L. Worsham, K. J. Rose, B. E. Ivins, J. R. Lowe, G. B. Howe, P. Mikesell, et al. 1993. Post-exposure prophylaxis against experimental inhalation anthrax. I. Infect. Dis. 167:1239-1243.
19. Friedlander, A. M. 2000. Anthrax: clinical features, pathogenesis, and potential biological warfare threat. Curr. Clin. Top. Infect. Dis. 20:335-349.
20. Heine, H. S., J. Bassett, L. Miller, J. M. Hartings, B. E. Ivins, M. L. Pitt, D. Fritz, S. L. Norris, and W. R. Byrne. 2007. Determination of antibiotic efficacy against Bacillus anthracis in a mouse aerosol challenge model. Antimicrob. Agents Chemother. 51:1373-1379.
21. Leighton, T. J., and R. H. Doi. 1971. The stability of messenger ribonucleic acid during sporulation in Bacillus anthracis. J. Biol. Chem. 246:3189-3195.
22. Pile, J. C., J. D. Malone, E. M. Eitzen, and A. M. Friedlander. 1998. Anthrax as a potential biological warfare agent. Arch. Intern. Med. 158:429-434.
23. Rayner, C. R., A. Forrest, A. K. Meagher, M. C. Birmingham, and J. J. Schentag. 2003. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin. Pharmacokinet. 42:1411-1423.
24. Rubino, C. M., P. Ambrose, B. Cirincione, A. Arguedas, L. Sher, E. Lopez, X. Sáez-Llorens, and D. M. Grasela. 2007. Pharmacokinetics and pharmacodynamics of gatifloxacin in children with recurrent otitis media: application of sparse sampling in clinical development. Diagn. Microbiol. Infect. Dis. 59: 67-74.
25. Welkos, S. L., T. J. Keener, and P. H. Gibbs. 1986. Differences in susceptibility of inbred mice to Bacillus anthracis. Infect. Immun. 51:795-800.